Clinical bottom line
Nail disease in psoriatic arthritis (PsA) is a common and often refractory manifestation that significantly impacts patient quality of life and may predict more severe joint involvement. Emerging therapies, including newer biologics and targeted agents, show promise in improving refractory nail psoriasis alongside articular symptoms. However, evidence remains limited and heterogeneous, warranting cautious interpretation. Clinicians should consider integrating nail-specific outcome measures in PsA management and remain attentive to evolving data on novel treatments targeting nail pathology.
What the evidence shows
Nail involvement occurs in up to 80% of patients with PsA and is strongly associated with enthesitis and distal interphalangeal joint disease, reflecting shared pathophysiology (Gladman et al., 2014; Sobolewski et al., 2017). Nail disease can precede or coincide with arthritis onset and is recognized as a predictor of PsA development in patients with psoriasis (Baran et al., 2014). The Nail Psoriasis Severity Index (NAPSI) and its modifications provide validated tools to quantify nail disease severity and monitor treatment response (Mease et al., 2011).
Traditional systemic therapies and conventional DMARDs often inadequately control nail symptoms, which tend to be more resistant than skin or joint manifestations (Veale et al., 2013). Recent case reports and small series suggest that newer biologics targeting interleukin (IL)-23/IL-17 pathways, such as tildrakizumab, may yield clinical improvement in refractory nail disease in PsA (Ismail et al., 2020). These agents may modulate the underlying enthesitis and inflammation driving nail pathology. Sequential biologic use guided by ultrasound detection of subclinical disease has also been proposed to optimize control of refractory PsA manifestations, including nail involvement (Latheef et al., 2022).
Despite these encouraging signals, robust randomized controlled trial data specifically addressing nail disease outcomes in PsA remain sparse. Most clinical trials focus on skin and joint endpoints, with nail disease often a secondary or exploratory outcome. Furthermore, nail disease in PsA may present heterogeneously, complicating assessment and response evaluation (Sobolewski et al., 2017). Rare reports of nail disease exacerbation following lymphoma or other immune perturbations highlight the complex immunopathogenesis and need for individualized management (Kallarackal et al., 2000).
Caveats and uncertainty
The evidence base for novel therapies in refractory PsA nail disease is limited by small sample sizes, observational designs, and lack of standardized outcome reporting. Many studies derive from psoriasis trials rather than PsA-specific cohorts, limiting direct applicability. The heterogeneity of nail involvement and overlap with skin psoriasis complicate attribution of treatment effects. Long-term safety and durability of response for newer agents in nail disease remain to be established.
Moreover, the pathophysiological mechanisms linking nail disease to joint inflammation in PsA are incompletely understood, raising questions about whether nail improvement necessarily predicts or parallels joint disease control. Ultrasound and imaging modalities to detect subclinical nail and entheseal inflammation are promising but not yet standardized in routine practice.
How this may change practice
Clinicians managing PsA should recognize nail disease as a significant and potentially refractory domain warranting targeted assessment and treatment. Incorporating validated nail severity indices such as NAPSI can aid in monitoring and therapeutic decision-making. Novel biologics targeting IL-23/IL-17 pathways may be considered for patients with persistent nail involvement despite conventional therapies, ideally within a multidisciplinary framework including dermatology.
Ultrasound evaluation may help identify subclinical inflammation guiding sequential biologic therapy in refractory cases, although this approach requires further validation. Awareness of the prognostic implications of nail disease may prompt earlier and more aggressive intervention to prevent joint damage.
Ongoing research and clinical trials focused on nail-specific outcomes in PsA are needed to refine treatment algorithms and optimize patient-centered care.